- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Quality of Life & Patient Reported Outcomes in Dry Eye Disease
Panelists underscore the importance of patient education in improving treatment adherence.
EP: 1.Overview of Dry Eye Disease (DED) Causes and Treatments
EP: 2.Adverse Events & Existing Treatment Options for Dry Eye Disease
EP: 3.Navigating Different Subtypes of Dry Eye Disease
EP: 4.Assessing Efficacy of Treatment Through Patient-Reported Outcomes
EP: 5.Updating Formularies: Considerations for Dry Eye Disease
EP: 6.Assessing the Economic Burden of Under Diagnosed Dry Eye Disease
EP: 7.Identifying Key Socioeconomic Burdens Associated with Dry Eye Disease
EP: 8.Resource Allocation in the Treatment of Dry Eye Disease
EP: 9.Quality of Life & Patient Reported Outcomes in Dry Eye Disease
EP: 10.Annual Health Care Costs of Managing Dry Eye Disease
EP: 11.Novel Treatments Targeting Symptoms & Causes of Dry Eye Disease
EP: 12.Evaluating Treatment Outcomes in Dry Eye Disease
EP: 13.Evaluating Economic Impact of Emerging Therapies for Dry Eye Disease
EP: 14.Concluding Thoughts on the Treatment of Dry Eye Disease
This is a video synopsis/summary of a Stakeholder Summit involving:
Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.
Kabiri discusses the significant impact of dry eye disease (DED) on quality of life, including higher rates of depression compared to other ocular conditions. Red, irritated eyes also affect self-image and enjoyment of activities. Patient perspectives on DED help identify educational gaps for improved adherence.
Haumschild then asks about strategies to improve DED adherence. Parekh notes the value of direct-to-consumer DED awareness campaigns in informing patients and driving inquiries regarding specialty care. Education around DED encompasses digital patient communities, eye care team counseling, pharmacy staff, professional societies, and industry. With DED’s rising prominence, education helps prevent misinformation, empowers patients to seek appropriate treatment, and facilitates proper self-management for better outcomes.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
